{"url_path":"/sec/rani/8-k/2026-06-30/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-30","source_url":"https://www.sec.gov/Archives/edgar/data/1856725/0001856725-26-000003-index.html","accession_number":"0001856725-26-000003","cik":"0001856725","ticker":"RANI","issuer_name":"Rani Therapeutics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1856725/0001856725-26-000003-index.html","primary_entity_key":"0001856725","primary_entity_name":"Rani Therapeutics Holdings, Inc."},"word_count":100,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nNumber\n\nExhibit Description\n\n10.1\n\n[Offer Letter, by and between Rani Therapeutics LLC and Nicholas Maestas dated June 24, 2026](rani-ex10_1.htm)\n\n10.2\n\n[Rani Therapeutics Holdings, Inc. 2026 Equity Inducement Plan](rani-ex10_2.htm)\n\n10.3\n\n \n\n[Form of Stock Option Agreement under Rani Therapeutics Holdings, Inc. 2026 Equity Inducement Plan](rani-ex10_3.htm)\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nRani Therapeutics Holdings, Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 29, 2026\n\nBy:\n\n/s/ Talat Imran\n\n \n\n \n\n \n\nTalat Imran\nChief Executive Officer"}